Table 1. LCRMP-1 and phosphorylated GSK3β expression in relation to clinical parameters and pathological characteristics*.
LCRMP-1 | p-GSK3β | |||||||
Category | Subcategory | Number | ≤50% (%) | >50% (%) | P | ≤70% (%) | >70% (%) | P |
Total patients | 142 | 102 (71.8) | 40 (28.2) | 73 (51.4) | 69 (48.6) | |||
Sex | Female | 78 | 55 (53.9) | 23 (57.5) | 0.7 | 44 (60.3) | 34 (49.3) | 0.188 |
Male | 64 | 47 (46.1) | 17 (42.5) | 29 (39.7) | 35 (50.7) | |||
Histological type† | Adenocarcinoma | 123 | 86 (87.8) | 37 (94.9) | 0.215 | 60 (85.7) | 63 (94.0) | 0.108 |
Squamous cell carcinoma | 14 | 12 (12.2) | 2 (5.1) | 10 (14.3) | 4 (6.0) | |||
Tumor size, cm | >3 | 74 | 57 (55.9) | 17 (42.5) | 0.151 | 41 (56.2) | 33 (47.8) | 0.32 |
≤3 | 68 | 45 (44.1) | 23 (57.5) | 32 (43.8) | 36 (52.2) | |||
Vascular invasion | Positive | 25 | 19 (18.6) | 6 (15.0) | 0.61 | 14 (19.2) | 11 (15.9) | 0.613 |
Negative | 117 | 83 (81.4) | 34 (85.0) | 59 (80.8) | 58 (84.1) | |||
Lymph node metastasis | Positive | 32 | 18 (17.7) | 14 (35.0) | 0.026 | 18 (24.7) | 14 (20.3) | 0.534 |
Negative | 110 | 84 (82.4) | 26 (65.0) | 55 (75.3) | 55 (79.7) | |||
Extranodal extension | Positive | 20 | 10 (9.8) | 10 (25.0) | 0.019 | 11 (15.1) | 9 (13.0) | 0.729 |
Negative | 122 | 92 (90.2) | 30 (75.0) | 62 (84.9) | 60 (87.0) | |||
Tumor stage | Stage I | 107 | 82 (80.4) | 25 (62.5) | 53 (72.6) | 54 (78.3) | ||
Stage II | 17 | 13 (12.8) | 4 (10.0) | 11 (15.1) | 6 (8.7) | |||
Stage III–IV | 18 | 7 (6.9) | 11 (27.5) | 0.004 | 9 (12.3) | 9 (13.0) | 0.505 | |
LCRMP-1 expression, % | >50 | 102 | – | – | – | 56 (76.7) | 46 (66.7) | 0.184 |
≤50 | 40 | – | – | 17 (23.3) | 23 (33.3) | |||
p-GSK3β expression, % | >70 | 69 | 46 (45.1) | 23 (57.5) | 0.184 | – | – | – |
≤70 | 73 | 56 (54.9) | 17 (42.5) | – | – |
*P values were calculated using a two-sided chi-squared test. Abbreviations: LCRMP-1, long-form collapsin response mediator protein-1; p-GSK3β, phosphorylated Glycogen synthase kinase-3β.
Adenosquamous carcinomas are not included.